Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

332.87USD
15 Feb 2019
Change (% chg)

$8.16 (+2.51%)
Prev Close
$324.71
Open
$328.09
Day's High
$333.19
Day's Low
$324.74
Volume
546,674
Avg. Vol
522,710
52-wk High
$388.67
52-wk Low
$249.24

Select another date:

Tue, Jan 29 2019

Photo

Biogen beats estimates on multiple sclerosis drugs sales

Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

UPDATE 2-Biogen beats estimates on multiple sclerosis drugs sales

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

CORRECTED-UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.

Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct

Jan 29 Biogen Inc reported a 6.6 percent rise in fourth-quarter revenue on Tuesday, driven by higher sales of its blockbuster muscle disease treatment Spinraza.

Fed Circuit declines to reconsider order upholding Biogen MS drug patents

A federal appeals court on Wednesday said it would not reconsider its recent decision affirming the validity of Biogen Inc’s key patent on its blockbuster multiple sclerosis drug Tecfidera.

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

UPDATE 1-U.S body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

Select another date: